The present invention relates to compositions comprising reagents which bindto thenovel protein TWEAK and to the use of TWEAK binding reagents to block thedevelopment of immunologic disorders. Immunological disorders are manifestedas awide variety of diseases and pathologies, including autoimmune diseases, and aneedexists for additional agents for treatment of these disorders. TWEAK bindingreagents ofthe invention include monoclonal antibodies, soluble TWEAK-receptor-Ig fusionproteins, or other molecules which modify the binding of TWEAK to itsreceptor(s).
